Sei Investments Co. Acquires 25,089 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sei Investments Co. boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 5.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 493,036 shares of the company's stock after purchasing an additional 25,089 shares during the period. Sei Investments Co.'s holdings in Teva Pharmaceutical Industries were worth $10,867,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TEVA. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after buying an additional 4,418,961 shares during the last quarter. Lingotto Investment Management LLP lifted its stake in Teva Pharmaceutical Industries by 2.6% in the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock valued at $599,320,000 after acquiring an additional 688,862 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in Teva Pharmaceutical Industries by 2.2% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock worth $573,822,000 after acquiring an additional 569,412 shares in the last quarter. State Street Corp increased its stake in shares of Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company's stock worth $351,402,000 after purchasing an additional 1,778,268 shares during the last quarter. Finally, AustralianSuper Pty Ltd increased its stake in shares of Teva Pharmaceutical Industries by 16.8% during the 4th quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company's stock worth $203,268,000 after purchasing an additional 1,329,319 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Remove Ads

Analysts Set New Price Targets

TEVA has been the subject of a number of recent research reports. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Thursday, March 27th. Bank of America reduced their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Finally, Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock traded down $0.45 during trading hours on Thursday, reaching $14.85. 8,174,233 shares of the company's stock were exchanged, compared to its average volume of 9,702,144. The business has a fifty day moving average price of $16.67 and a 200-day moving average price of $18.04. The stock has a market capitalization of $16.83 billion, a P/E ratio of -10.24, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.